In a report released today, Caroline Palomeque from Maxim Group maintained a Buy rating on VistaGen Therapeutics (VTGN), with a price target of $6. The company’s shares opened today at $1.30.
Palomeque commented:
“VistaGen presented additional positive data from its ‘pilot’ Phase 3 trial of PH94B, its pherine nasal spray for social anxiety disorder (SAD). The poster presentation was shown at the ongoing America (ADAA) conference in Chicago.”
According to TipRanks.com, Palomeque has currently no stars on a ranking scale of 0-5 stars, with an average return of -4.6% and a 45.3% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as AzurRx BioPharma Inc, Daré Bioscience Inc, and Agile Therapeutics.
VistaGen Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.44 and a one-year low of $0.81. Currently, VistaGen Therapeutics has an average volume of 275.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines for depression and other diseases and disorders of the central nervous system. It focuses on AV-101 product, an oral, non-opioid and non-sedating therapy that offers the potential to be a new at-home treatment for multiple central nervous system indications with high-unmet medical need. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
